Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoprotein

Li-Xin Zhu, Jing Liu, Ying-Chun Li, Yu-Ying Kong, Caroline Staib, Gerd Sutter, Yuan Wang, Guang-Di Li

Abstract

AIM: To study HCV polyprotein processing is important for the understanding of the natural history of HCV and the design of vaccines against HCV. The purpose of this study is to investigate the affection of context sequences on hepatitis C virus (HCV) E2 processing.

METHODS: HCV genes of different lengths were expressed and compared in vaccinia virus/T7 system with homologous patient serum S94 and mouse anti-serum M2116 raised against E. coli- derived E2 peptide, respectively. Deglycosylation analysis and GNA (Galanthus nivalis) lectin binding assay were performed to study the post-translational processing of the expressed products.

RESULTS: E2 glycoproteins with different molecular weights (75kDa and 60kDa) were detected using S94 and M2116, respectively. Deglycosylation analysis showed that this difference was mainly due to different glycosylation. Endo H resistance and its failure to bind to GNA lectin demonstrated that the higher molecular weight form (75kDa) of E2 was complex-type glycosylated, which was readily recognized by homologous patient serum S94. Expression of complex-type glycosylated E2 could not be detected in all of the core-truncated constructs tested, but readily detected in constructs encoding full-length core sequences.

CONCLUSION: The upstream conserved full-length core coding sequence was required for the production of E2 glycoproteins carrying complex-type N-glycans which reacted strongly with homologous patient serum and therefore possibly represent more mature forms of E2. As complex-type N-glycans indicated modification by Golgi enzymes, the results suggest that the presence of full-length core might be critical for E1/E2 complex to leave ER. Our data may contribute to a better understanding of the processing of HCV structural proteins as well as HCV morphogenesis.

Zhu LX, Liu J, Li YC, Kung YY, Staib C, Sutter G, Wang Y, Li GD. Full-length core sequence dependent complex-type glycosylation of hepatitis C virus E2 glycoprotein. World J Gastroenterol 2002;8(3):499-504

INTRODUCTION

Hepatitis C virus (HCV), the major cause of post-transfusion and community-acquired non-A, non-B hepatitis[1-3], is a member of the Flaviviridae family[4]. This virus has a positive-sense, single stranded RNA genome of about 9.6 kb, which encodes a polyprotein precursor of about 3000 amino acids. The polyprotein is further processed into various precursors and mature viral proteins[4,5]. The structural proteins are encoded in the order NH2-core-E1-E2-P7, which are processed into core (C), E1, E2, and P7 by host membrane-associated signal peptidases(s)[6,7]. The downstream nonstructural region is processed by a viral metalloprotease and a viral serine protease located at the N-terminus of NS3[8]. The core protein is thought to constitute the viral capsid with E1 and E2 being the virus envelope proteins. Numerous studies have shown that E1 and E2 are heavily glycosylated and associate to form a noncovalent heterodimeric complex[8,9]. E1 and E2 are believed to be type I transmembrane proteins with an N-terminal glycosylated ectodomain and a C-terminal hydrophobic anchor.

The lack of an efficient in vitro cell culture system for productive HCV propagation[10,11] and low levels of HCV particles in the liver tissues or blood of infected patients[12,13] have hampered the study of native viral proteins. Fortunately, a variety of prokaryotic and eukaryotic expression systems have proved useful for the production and characterization of HCV encoded proteins[14-16]. However, diverse findings have been reported, regarding the molecular weights of E2, which most likely is a reflection of the differences in efficiency of HCV polyprotein processing and post-translational modification achieved in the particular systems[8,14,16]. In this study, the E2 expression of recombinant plasmids carrying various length of HCV C-E1-E2 coding sequences was analyzed in the vaccinia virus/bacteriophage T7 RNA polymerase expression system[17]. The results suggest that the upstream conserved core coding sequence is required for the production of E2 glycoproteins carrying complex-type N-glycans which react strongly with homologous patient serum and therefore possibly represent more mature forms of E2.

MATERIALS AND METHODS

Cells and viruses

Human HeLa (ATCC #CCL-2) and monkey BS-C-1 (ATCC #CCL-26) cells were maintained in Dulbecco’s modified essential medium (DMEM/HG) supplemented with 5% heat-inactivated fetal calf serum (FCS) at 37°C in a 5% CO2 atmosphere. Recombinant vaccinia virus vT7T that expresses the bacteriophage T7 RNA polymerase gene under the control of vaccinia virus early/late promoter P7.5 was generated and propagated as previously described[18]. PFU (plaque forming unit) titration was performed on BS-C-1 cell monolayers.

Plasmid constructions

The vaccinia virus/T7 promoter expression vector pTM1 was kindly provided by Bernard Moss (NIH, Bethesda, USA) and all of the expression plasmids carrying HCV cDNA encoding structural proteins described below were derived from pTM1. Figure 1 depicts the HCV gene fragment in the expression plasmids. Plasmids pCEH-2 (1-730)
and pEH containing HCV C, E1 and E2 gene of subtype 1b (Genbank accession #D10934) were described previously [34]. Briefly, cDNA sequences encoding HCV polyprotein amino acids 192 to 730 were inserted into pTM1 to obtain pEH. HCV sequences encoding complete C were fused with the E1/E2 sequences of pEH to result in plasmid pCEH-2(1-730). The latter plasmid served as basis for PCR cloning to generate plasmids pCEH(1-341), pCEH-2(108-730), pCEH-2(120-730), pCEH-2(137-730), pCEH-2(156-730), pCEH-2(167-730), pCEH-2(1-661) and pTM1/EH(192-661) for the expression of 5' or/and 3' truncated HCV sequences encoding HCV structural proteins. The transient expression products of plasmids pCEH-2(1-730) and pCEH-2(1-661), which contain HCV cDNA encoding the structural region terminating at amino acid 730 and 661 of the polyprotein respectively, were analyzed by Western blot using polyclonal mouse serum ME2116 raised against E.coli-derived HCV E2 polypeptide (aa 450-565), and anti-HCV human serum S268 at a dilution of 1:500 (kindly provided by Lu Z., Shanghai Ruijin Hospital, China), anti-E2 mouse polyclonal antibody M2116 at a dilution of 1:300 (raised against E. Coli-derived HCV E2 polypeptide aa450 to 565), and anti-E1 rabbit polyclonal antibody R2113C at a dilution of 1:250 (raised against an E. coli-derived C-terminally truncated HCV E1 fragment).

**Characterization of N-glycans on expressed E2 glycoproteins**

For deglycosylation analysis, cell pellets were directly lysed in denaturing buffer provided by the manufacturer and digested with PNGase F (NEB) or Endo H (NEB) for 2 hours at 37°C. The type of N-glycans on expressed E2 glycoproteins was also analyzed by testing its ability to bind to GNA (Galanthus nivalis lectin). HeLa cells infected with vTT7 and transfected with pCEH-2(1-730) were collected by scraping, washed in cold PBS, and then lysed with lysis buffer (50mM Tris-HCl, 150mM NaCl, 0.5% Nonidet P-40, 1mM PMSF). After centrifugation at 10000g, the supernatant was used for Western blotting experiment.

**RESULTS**

**Detection of E2 glycoproteins of different Molecular Weights using antibodies of distinct origins**

The hybrid vaccinia virus/T7 bacteriophage RNA polymerase expression system was used to study the expression of the HCV structural proteins. The transient expression products of plasmids pCEH-2(1-730) and pCEH-2(1-661), which contain HCV cDNA encoding the structural region terminating at amino acid 730 and 661 of the polyprotein respectively, were analyzed by Western blot using polyclonal mouse serum ME2116 raised against E.coli-derived E2 protein [36]. E2 products with apparent molecular weights (MWs) of ~60kDa and ~50kDa were detected for pCEH-2(1-730) and pCEH-2(1-661) respectively (Figure 2, lane 1, 3). The apparent molecular weights were higher than calculated values, which, along with the heterogeneous appearance of the detected bands, suggested that these were glycosylated expression products. The lower molecular weight of the E2 species obtained from expression of pCEH-2(1-661) in comparison to pCEH-2(1-730) was consistent with the introduced truncation at the 3' end of the E2 coding sequences leading to the loss of 70 amino acids in the recombinant polypeptide backbone.

**Western blot analysis**

Cell lysates were separated by reducing SDS-PAGE and then transferred onto nitrocellulose membranes (Schleicher & Schuell). Blocking was done using 5% fat-free milk powder. For immunodetection of HCV proteins, blots were incubated with primary antibodies, washed, and incubated with 1000 fold diluted HRP-protein A (Sigma). The membranes were then washed again and reactive proteins were detected using the ECL system (Amersham Pharmacia Biotech) according to the manufacturers’ instructions. The primary antibodies used in this study include: anti-HCV human serum S94 at a dilution of 1:500 (kindly provided by Wang, Y., Beijing University, China), anti-HCV human serum S268 at a dilution of 1:500 (kindly provided by Lu Z., Shanghai Ruijin Hospital, China), anti-E2 mouse polyclonal antibody M2116 at a dilution of 1:300 (raised against E. Coli-derived HCV E2 polypeptide aa450 to 565), and anti-E1 rabbit polyclonal antibody R2113C at a dilution of 1:250 (raised against an E. coli-derived C-terminally truncated HCV E1 fragment).

![Figure 1](image1.png)

**Figure 1** Schematic maps of HCV coding sequences inserted into the plasmid pTM1 and expressed under transcriptional control of the bacteriophage T7 pol promoter. Numbers refer to amino acids of the HCV polyprotein.

**Figure 2** Detection of E2 glycoprotein species of different molecular masses. Transient expression products were analyzed by Western blot with antibodies of distinct origin: mouse polyclonal antibody M2116 (lane 1, 2, 3); HCV patient serum S94 (lane 4, 5, 6); HCV patient serum S268 (lane 7, 8); rabbit polyclonal antibody R2113C (lane 9, 10, 11). Empty vector pTM1 was used as the negative control. HCV-specific protein bands are indicated by arrowheads. The plasmids used for transfection are indicated at the top of the lanes.
The expression products were also analyzed with HCV patient serum S94. Multiple prominent bands were detected for pCEH-2(1-730) and pCEH-2(1-661), but not for vector plasmid pTM1, representing expressed HCV structure proteins and possibly some precursors. The bands of ~75 kDa and ~66 kDa (Figure 2, lane 4, 6), which again consistent with the different length of E2 coding sequence in both plasmids, should represented the E2 proteins, although their MWs were higher than that detected by ME2116. It is worth noting that the analyzed HCV cDNA originated from the same patient from whom S94 was collected. The core antigen and some precursors of expression products could also be detected by another HCV patient serum S268, but we could not detect the E2-specific 75kDa band (Figure 2, lane 8), which could be attributed to the high variability of the E2 glycoprotein.

The antibody dependent detection of different E2 glycoprotein species was surprising. To rule out that the E2 bands of higher MW is the uncleaved E1-E2 precursors, the expression products from pCEH-2(1-730) were analyzed with anti-E1 rabbit sera. A heavy band of about 30kDa was detected, possibly representing multiple forms of E1 proteins (Figure 2, lane 10), while no E1-specific band with higher MW was detected. Another possible explanation could be that E2 polypeptides of varying sizes were synthesized due to incomplete or non-specific processing of the polypeptide. This hypothesis was abandoned when we subjected recombinant proteins to deglycosylation with PNGase F treatment, because there were multiple HCV polyprotein precursor proteins of about 30000 reacted strongly with S94 and unglycosylated E2 seemed to react weakly with S94 (unpublished data). However, the highly glycosylated, S94-reactive E2 band was resistant to Endo H digestion (Figure 2, lane 10), while not well detected by ME2116. The S94-reactive E2 bands disappeared after PNGase F digestion (Figure 4B). It was difficult to detect the deglycosylated E2 with S94 after PNGase F treatment, because there were multiple HCV polyprotein precursor proteins of about 30000 reacted strongly with S94 and unglycosylated E2 seemed to react weakly with S94 (unpublished data). However, the highly glycosylated, S94-reactive E2 band remained after Endo H digestion (Figure 4B). The glycan type of different E2 species expressed from pCEH-2(1-730) was also analyzed by testing their ability to bind to GNA lectin. GNA is specific for the non-reducing end of α-D-mannosyl residue of glycoconjugate and therefore can be used to probe the presence of high mannose type or hybrid type glycans on glycoproteins. The ME2116-reactive E2 species could quantitatively bind to and be eluted from GNA-agarose, whereas no obvious binding could be demonstrated for S94-reactive E2 species (Figure 5).

The resistance of S94-reactive E2 glycoprotein species to Endo H digestion together with the fact that it could not bind to GNA indicates that the S94-reactive E2 protein carries complex-type glycans.

Altogther, the above results suggest that the 75kDa and 66kDa bands detected by S94 are HCV E2 glycoproteins of heavier glycosylation and thus higher molecular weight.

**ME2116- and S94-reactive E2 glycoproteins carried different types of N-glycans**

Since ME2116- and S94-reactive E2 species had polypeptide backbones of the same size, the difference in apparent molecular weight and antibody reactivity could only be attributed to differences in the degree and/or type of glycosylation. The glycan type on different E2 species expressed from pCEH-2(1-730) was then analyzed by testing their sensitivity to PNGase F and Endo H. PNGase F hydrolyzes all types of N-glycan chains from glycoproteins and glycopeptides unless they carry α-1-3 linked core fucose residues present in insect and plant glycoproteins, while Endo H cleaves only high mannose structures and hybrid structures on N-linked oligosaccharides of glycoproteins. Figure 4A shows that the ME2116-reactive E2 species was sensitive to both PNGase F and Endo H digestion. The S94-reactive E2 species disappeared after PNGase F digestion (Figure 4B). It was difficult to detect the deglycosylated E2 with S94 after PNGase F treatment, because there were multiple HCV polyprotein precursor proteins of about 30000 reacted strongly with S94 and unglycosylated E2 seemed to react weakly with S94 (unpublished data). However, the highly glycosylated, S94-reactive E2 band remained after Endo H digestion (Figure 4B). The glycans of different E2 species expressed from pCEH-2(1-730) were also analyzed by testing their ability to bind to GNA lectin. GNA is specific for the non-reducing end of α-D-mannosyl residue of glycoconjugate and therefore can be used to probe the presence of high mannose type or hybrid type glycans on glycoproteins. The ME2116-reactive E2 species could quantitatively bind to and be eluted from GNA-agarose, whereas no obvious binding could be demonstrated for S94-reactive E2 species (Figure 5).

The resistance of S94-reactive E2 glycoprotein species to Endo H digestion together with the fact that it could not bind to GNA indicates that the S94-reactive E2 protein carries complex-type glycans.
When using mouse antibody M_2116, recombinant E2 of ~60kDa and ~50kDa could be detected upon expression of all constructs tested (Figure 6A). Patient serum S94 allowed detection of E2 for pCEH-2(1-730) and pCEH-2(1-661) with full-length core coding sequences (Figure 6B, lanes 7, 9), similar to that described in Figure 2. In contrast, no E2 products could be visualized after expression of constructs containing no or only partial core sequences (Figure 6B, lanes 1-6). Interestingly, deletion of E1 coding sequences had no significant effect on the synthesis of S94 detectable E2 protein (Figure 6B, lane 10). These results suggest that the presence of complete HCV core sequence is crucial for the expression and/or post-translational processing of the complex-type glycosylated form of E2.

**DISCUSSION**

In this study, various constructs of HCV cDNAs placed under transcriptional control of the bacteriophage T7 promoter were transiently expressed using vaccinia virus/T7 system. Upon characterization of the HCV gene products with different antibodies, two species of E2 with different MWs were identified in the expression products of the same plasmid. The high molecular weight forms of E2 were readily recognized by a patient serum, but displayed weak reactivity with antibodies raised against E. coli derived E2. These high molecular weight forms of E2 were not likely produced from inefficient proteolytical processing at the E1/E2 boundary as these proteins were not stained with E1-specific antibodies. Efficient processing at E1/E2 was confirmed by deglycosylation analysis. The difference of the MWs of E2 species detected by S94 and by M_2116 was therefore mainly due to different N-glycosylation. The S94-reactive E2 glycoproteins, which were resistant to Endo H digestion and could not bind to GNA, carry complex-type glycans.

The specific recognition of the complex-type glycosylated E2 but not the high-mannose-type glycosylated E2 by homologous patient serum S94 suggested that the former could be a better representation of native E2 proteins on HCV virions. Similar results were also reported by Inudoh et al. By comparing the reactivity of complex-type glycosylated E2 and the high-mannose-type glycosylated E2 with different patient sera, they demonstrated that the former is superior in diagnosing HCV infection. Their results and our results reported here are in concordance with the finding that E2 protein on patient derived virions contained complex-type sugars indicating Golgi-specific modification.

Expression of full-length or C-terminally truncated envelop proteins in eukaryotic cells has demonstrated that E1 and E2 are retained within the ER membrane system due to the presence of ER-retention signals in the C-termini of both envelope proteins. However, recent study indicates that HCV E2 proteins could also present in the Golgi apparatus of the stably transfected cell line expressing HCV C-E1-E2:NS2 fragment. A possible explanation could be that Martire et al. used an HCV gene fragment including full-length core sequences in their study while structural protein sequences without full-length core sequences were used to study the localization of envelop proteins. The results reported here demonstrated that the complex-type glycosylated, possibly more mature form of E2 is only detectable upon co-expression of the complete HCV core coding sequence. Deletion of the first 107 N-terminal core amino acid residues was obviously sufficient to abrogate production of complex-glycosylated E2. This result suggest that the core protein might allow for targeting the envelope glycoproteins to Golgi-specific modification, which could be a key step in the morphogenesis of HCV virions. HCV-like particles were observed when HCV cDNA encoding whole core, E1 and E2 was expressed in baculovirus-insect expression system. After binding of core to the E1-E2 complex statically located on the ER membrane, virus-like particles might be formed and the conformation of E1-E2 complex changed, which could result in the abrogation of the ER-retention
signal for the E1-E2 complex. Then the virus-like particles might migrate along the secretion pathway, where E2 (and E1) proteins undergo more complex glycosylation by the Golgi enzymes.

In summary, upon expression of recombinant HCV core, E1, and E2 sequences, the E2 proteins of different glycosylations could be identified. The complex-glycosylated E2 protein might represent a more mature form of E2 and its formation required the conserved core coding sequences. Our data may contribute to a better understanding of the processing of HCV structural proteins as well as HCV morphogenesis.

ACKNOWLEDGMENT

We thank Wang, Y. and Lu, Z. for providing the HCV clones and the HCV specific patient sera.

REFERENCES

1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. In vitro processing of HCV structural proteins as well as HCV morphogenesis.

2 Kuo G, Choo QL, Alter HJ, Gitnick GL, Redecker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeyer GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362

3 Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1989; 9: 1225-1238

4 Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos J, Watanabe Y, Takeuchi K, Suzuki T, Katayama T, Takebe Y, Tai T, Yamashita K, Ogata-Arakawa M, Koide N, Muramatsu T. Characterization of hepatitis C virus in mammalian cells.

5 Houghton M, Weiner A, Han J, Kuo G, and Choo QL. Molecular virology of hepatitis C. Hepatology 1991; 14: 381-388

6 Harada S, Watanabe Y, Takeuchi K, Suzuki T, Katayama T, Takebe Y, Saito I, Miyamura T. Expression of processed core protein of hepatitis C virus in mammalian cells. J Virol 1991; 65: 3015-3021

7 Hikijaka M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991; 88: 2451-2455

8 Miret M, Delaporte E, Grakoui A, McCourt DW, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. J Virol 1993; 67: 6753-6761

9 Ralston R, Thudium K, Berger K, Kuo G, Houghton M, Choo QL. Characterization of hepatitis C virus envelop glycoprotein complexes expressed by recombinant vaccinia virus. J Virol 1993; 67: 4017-4026

10 Lohmann R, Korn R, Koch J, Herian U, Theilmann L, Bartschagner R, Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 1991; 75: 1252-1264

11 Spaete RR, Alexander D, Rugroden ME, Choo QL, Berger K, Crawford K, Kuo C, Houghton M. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system. Hepatology 1993; 17: 763-771

12 Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Posttranscriptional hepatitis C virus protein E1 in Escherichia coli. J Virol Methods 1994; 49: 343-351

13 Hikijaka M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities in recombinant hepatitis C virus RNAs. Virology 1994; 200: 387-397

14 Eckart MR, Selby M, Masiarz F, Lee C, Berger K, Crawford K, Kuo C, Houghton M. Identiﬁcation and characterization of hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 1437-1449

15 Grakoui A, Woclowski C, Lin C, Feistone SM. Rice CM. Expression and identiﬁcation of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385-1395

16 Matsuzara Y, Suzuki T, Suzuki R, Sato M, Aizaki H, Saito I, Miyamura T. Processing of E1 and E2 glycoprotein of hepatitis C virus expressed in mammalian and insect cells. Virology 1994; 205: 141-150

17 Hiramatsu N, Dash S, Gerber MA. HCV cDNA transfection to HepG2 cells. J Virology 1994; 7: 2467-2476

18 Rumin S, Berthillon P, Tanaka E, Kiyosawa K, Traubaud MA, Bizollon E, Piolet C, Martinet C, Roux M, Billeter M, Carmona-Paez G, Trepo C. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999; 80: 3007-3018

19 Lohmann V, Korn R, Koch J, Herian U, Theilmann L, Bartschagner R, Host-range analysis of hepatitis C virus RNA's in a hepatoma cell line. Science 1999; 285: 110-113

20 Song QZ, Hao F, Min F, Ma QY, Liu GD. Hepatitis C virus infection of human hepatoma cell line 7212 in vitro. World J Gastroenterol 2001; 7: 685-689

21 Bartschagner R, Lohmann V. Novel cell culture systems for the hepatitis C virus. Antiviral Res 2001; 52: 1-17

22 Lohmann V, Korn R, Dobierzewska A, Bartschagner R. Mutations in hepatitis C virus RNA's conferring cell culture adaptation. J Virol 2001; 75: 1437-1449

23 Leitch C, Lohmann V, Rutter G, Kurpanek B, Bartschagner R. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system. Hepatology 1993; 17: 763-771

24 Yan BS, Liao LY, Leou K, Chang YC, Syu WJ. Truncating the putative membrane associated region circumvents the difficulty of expressing hepatitis C virus protein E1 in Escherichia coli. J Virol Methods 1994; 49: 343-351

25 Zhu LX, Kong YY, Wang Y, Li GD. Effect of downstream sequence on the cleavage of envelop protein signal sequence in hepatitis C virus. Virology 1999; 285: 107-110

26 Xiao L, Sidhu R, Belshaw R, Yeh B, Feinstone SM, Rice CM. Identification and characterization of hepatitis C virus polyprotein cleavage products. Virology 1994; 200: 387-397

27 Tanaka T, Kimura K, Shimotohno K. Expression and identification of hepatitis C virus polyprotein cleavage products. J Biol Chem 1995; 270: 23057-23064

28 Liu J, Zhu L, Zhang X, Lu M, Kong Y, Wang Y, Li G. Expression, purification, immunological characterization and application of E2-derived hepatitis C virus E2 proteins. Biotechnology and Applied Biotechnology 2001; 34: 109-119

29 Kaku H, Goldstein IJ. Snowdrop lectin. Biochemistry 1991; 30: 9157-9162

30 Hsu HH, Donets M, Greenberg HB, Feinstone SM. Characterization of hepatitis C virus RNAs. Virology 1993; 197: 225-235

31 Lohmann R, Korn R, Koch J, Herian U, Theilmann L, Bartschagner R. Host-range analysis of hepatitis C virus RNA's in a hepatoma cell line. Science 1999; 285: 110-113

32 Zhu LX, Kong YY, Wang Y, Li GD. Effect of downstream sequence on the cleavage of envelop protein signal sequence in hepatitis C virus. Virology 1999; 285: 107-110

33 Xiao L, Sidhu R, Belshaw R, Yeh B, Feinstone SM, Rice CM. Identification and characterization of hepatitis C virus polyprotein cleavage products. Virology 1994; 200: 387-397

34 Leitch C, Lohmann V, Rutter G, Kurpanek B, Bartschagner R. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system. Hepatology 1993; 17: 763-771

35 Yan BS, Liao LY, Leou K, Chang YC, Syu WJ. Truncating the putative membrane associated region circumvents the difficulty of expressing hepatitis C virus protein E1 in Escherichia coli. J Virol Methods 1994; 49: 343-351

36 Xiao L, Sidhu R, Belshaw R, Yeh B, Feinstone SM, Rice CM. Identification and characterization of hepatitis C virus polyprotein cleavage products. Virology 1994; 200: 387-397

37 Hikijaka M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991; 175: 220-228

38 Kikkawa H, Arai A, Iwamoto H, Hata T, Sato S, Takahashi T, Takahashi Y, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 4665-4675

39 Hikijaka M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993; 67: 4665-4675

40 Eckart MR, Selby M, Masiarz F, Lee C, Berger K, Crawford K, Kuo C, Kuo G, Houghton M, Choo QL. Characterization of hepatitis C virus envelope glycoproteins. J Virol Meth-
43 Shibuya N, Berry JE, Goldstein IJ. One-step purification of murine IgM and human alpha 2-macroglobulin by affinity chromatography on immobilized snowdrop bulb lectin. Arch Biochem Biophys 1988; 267: 676-680

44 Inadom H, Nyunoya H, Tanaka T, Hijikata M, Kato N, Shimotohno, K. Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. Vaccine 1996; 14: 1590-1596

45 Sato K, Okamoto H, Aihara S, Hoshi Y, Tanaka T, Mishiro S. Demonstration of sugar moiety on the surface of HCV recovered from the circulation of infected humans. Virology 1993; 196: 354-357

46 Cocquerel L, Duvet S, Meunier JC, Pillez A, Cacan R, Wychowski C, Dubuisson J. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J Virol 1999; 73: 2641-2649

47 Flint M, McKeating JA. The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. J Gen Virol 1999; 80: 1943-1947

48 Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, Wychowski C, Dubuisson J. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem 1998; 273: 32088-32095

49 Cocquerel L, Meunier JC, Pillez A, Wychowski C, Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 1998; 72: 2183-2191

50 Mottola G, Jourdan N, Castaldo G, Malagolini N, Lahm A, Serafini-Cessi F, Migliaccio G, Bonatti A S. New determinant of endoplasmic reticulum localization is contained in the juxtamembrane region of the ectodomain of hepatitis C virus glycoprotein E1. J Biol Chem 2000; 275: 24070-24079

51 Martire G, Viola A, Iodice L, Lotti LV, Gradini R, Bonatti S. Hepatitis C virus structural proteins reside in the endoplasmic reticulum as well as in the intermediate compartment/cis-Golgi complex region of stably transfected cells. Virology 2001; 280: 176-182

52 Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 3827-3836